Christie Impact Report 2025

RIGHT Artist’s impression of the new Pathology Centre

scanner in Manchester will be a flagship facility for the North, demonstrating the value of state-of-the-art PET-CT in providing for a diverse population with a wide range of significant health needs. We hope to have the scanner operational by Summer 2026. Pathology development Pathology, which involves examining cells and tissue and providing testing and screening (including for clinical trials), is essential to every patient’s journey at The Christie. The hospital currently conducts over 1 million tests annually, and as a leading provider it also serves other hospitals regionally and nationally. The current location and condition of the pathology department is no longer fit for purpose in terms of its size, layout and the ability to house new technology. The development of a new pathology centre will improve the patient experience and facilitate high quality research in line with our Charitable objectives. Once operational, the new pathology facility is expected to significantly increase sample throughput and turnaround times,

all without the need to increase staffing levels. The building will sit alongside a new cutting-edge scanning centre which has already received planning approval. One of the key elements of our strategy is to explore new ways of income generation. Social investment is investment that’s intended to deliver a positive social impact, as well as a financial return on the original investment. The construction of the new pathology facility is the Charity’s first social investment opportunity and will be managed by Northern Pathology Developments Limited, which is a subsidiary of The Christie Charity. We hope to explore other social investment opportunities in the near future. It is anticipated that work will begin onsite in Autumn 2025 and complete by Autumn 2026.

The Christie Charity Impact Report 2024/25 27